Showing 3301-3310 of 5910 results for "".
- Researchers Identify How Multiple Genes Impact Vision Development and Result in Rare Sight Disorderhttps://modernod.com/news/researchers-identify-how-multiple-genes-impact-vision-development-and-result-in-rare-sight-disorder/2480744/
- Heru Featured in Scientific Program with Hands-On Demonstrations at the 2022 Vision Expo East Annual Meetinghttps://modernod.com/news/heru-featured-in-scientific-program-with-hands-on-demonstrations-at-the-2022-vision-expo-east-annual-meeting/2480739/Heru, a provider of vision diagnostics, announced that the company will be featuring two new testing moda
- Innovega Grants Commercial License of its Next-Generation Display Eyewear to Global Supplierhttps://modernod.com/news/innovega-grants-commercial-license-of-its-next-generation-display-eyewear-to-global-supplier/2480728/Innovega finalized a definitive licensing agreement with one of the world's leading providers of assistive technology for the visually impaired, including the legally blind. This is the first commercial licensing agreement for Innovega’s next-generation display eyewear
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via
- Alcon Debuts Dailies Total1 for Astigmatism, Other Eye Care Innovations at SECO 2022https://modernod.com/news/alcon-debuts-dailies-total1-for-astigmatism-other-eye-care-innovations-at-seco-2022/2480694/
- UArizona Engineer Leads $1M Project to Fight Vision Losshttps://modernod.com/news/uarizona-engineer-leads-1m-project-to-fight-vision-loss/2480692/Eye infections are common in rural farming communities. A scratch on the cornea caused during agricultural work can get infected and turn into a scar, then an ulcer. These corneal ulcers cause blindness and visual impairment in 4.3 million people worldwide every year, according to data published
- Heru Appoints Former Amazon Executive Brandon Barber as Chief Marketing Officerhttps://modernod.com/news/heru-appoints-former-amazon-executive-brandon-barber-as-chief-marketing-officer/2480679/Heru has announced that veteran tech industry executive Brandon Barber has joined the company as Chief Marketing Officer, effective February 14. “Brandon is a proven strategic and tactical leader whose depth of experience will greatly benefit Heru as we continue to red
- Lighthouse Guild to Launch New Technology Center For Blind and Visually Impaired in Manhattanhttps://modernod.com/news/lighthouse-guild-to-launch-new-technology-center-in-manhattan/2480669/Lighthouse Guild is launching its new Technology Center with a special event led by Calvin Roberts, MD, and featuring demonstrations and discussion from Lighthouse Guild clients, community leaders, and vision loss experts,
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin